Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications
April 21 (Reuters) - Immunovant Inc IMVT.O:
IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN’S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402
IMMUNOVANT INC - ERIC VENKER APPOINTED AS CEO OF IMMUNOVANT
IMMUNOVANT INC - TIAGO GIRAO APPOINTED AS CFO OF IMMUNOVANT
IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 IN SJD, STUDY TO INITIATE SUMMER 2025
IMMUNOVANT INC - CURRENT CASH BALANCE PROVIDES RUNWAY THROUGH GRAVES’ DISEASE READOUT IN 2027
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?

Tradingkey







